Deferoxamine: iron chelator that decreases ability of free iron in brain tissue to cause oxidative injury
Phase I Study of deferoxamine mesylate (DFO) in patients with ICH demonstrated tolerability of doses up to 62mg/kg/day to max of 6000 mg/d x 5 days without major safety concerns.
Pilot trial of same dosage x 3 days shows lower perihematomal edema in patients treated with deferoxamine.
Phase 2 trial at this dose stopped due to increased occurrence of ARDS.
Recruitment for lower-dose phase 2 iDEF trial ongoing.
Burns, J., Fisher, J. and Cervantes-Arslanian, A. (2018). Recent Advances in the Acute Management of Intracerebral Hemorrhage. Neurosurgery Clinics of North America, 29(2), pp.263-272.